- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00329719
Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma
A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma
Přehled studie
Postavení
Detailní popis
Primary Objective -
Phase I (closed to accrual as of 01/11/2008):
To establish a maximum tolerable dose of temsirolimus in combination with sorafenib in patients with recurrent glioblastoma not receiving enzyme-inducing anticonvulsants (EIACs).
Phase II (closed to accrual as of 12/07/2012):
To assess the efficacy of temsirolimus and sorafenib in the treatment of recurrent glioblastoma in non-EIAC patients as measured by progression-free survival status at six months (PFS6).
Secondary Objectives -
Phase I (closed to accrual as of 01/11/2008):
I. To define the safety profile of temsirolimus and sorafenib in non-EIAC patients.
II. To assess the evidence of antitumor activity.
Phase II (closed to accrual as of 12/07/2012):
I. To assess the safety and toxicities of temsirolimus and sorafenib in the above-noted patient populations.
Outline: This is a multicenter, phase I, dose-escalation study followed by a phase II study.
Phase I (Arm A): Patients receive sorafenib orally (PO) twice daily (BID) on days 1-28 and temsirolimus intravenously (IV) over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of temsirolimus until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Phase II: Patients are assigned to 1 of 3 treatment groups.
Group 1 (Arm B): Patients receive sorafenib and temsirolimus as in phase I at the MTD. (patients not undergoing surgery)
Group 2 (Arm C): Patients receive sorafenib PO BID on days 1-8 (15 doses) and temsirolimus IV at the MTD on day 1. Patients undergo surgery on day 8. (patients undergoing surgery) After recovering from surgery, patients receive sorafenib and temsirolimus as in phase I at the MTD.
Group 3 (Arm D): Patient receive sorafenib and temsirolimus as in phase I at the MTD. (patients who have received prior anti-vascular endothelial growth factor [VEGF] therapy and are not undergoing surgery)
Biopsy or resected tissue and blood are collected prior to treatment (usually at diagnosis) and analyzed for biomarkers. After completion of study treatment, patients are followed every 6 months for 5 years and then annually thereafter.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Alaska
-
Anchorage, Alaska, Spojené státy, 99508
- Providence Alaska Medical Center
-
-
Arizona
-
Scottsdale, Arizona, Spojené státy, 85259
- Mayo Clinic in Arizona
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
-
Florida
-
Jacksonville, Florida, Spojené státy, 32224-9980
- Mayo Clinic in Florida
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Aurora, Illinois, Spojené státy, 60504
- Rush - Copley Medical Center
-
Bloomington, Illinois, Spojené státy, 61704
- Illinois CancerCare-Bloomington
-
Bloomington, Illinois, Spojené státy, 61701
- Saint Joseph Medical Center
-
Canton, Illinois, Spojené státy, 61520
- Illinois CancerCare-Canton
-
Canton, Illinois, Spojené státy, 61520
- Graham Hospital Association
-
Carthage, Illinois, Spojené státy, 62321
- Illinois CancerCare-Carthage
-
Carthage, Illinois, Spojené státy, 62321
- Memorial Hospital
-
Chicago, Illinois, Spojené státy, 60612
- Rush University Medical Center
-
Decatur, Illinois, Spojené státy, 62526
- Heartland Cancer Research NCORP
-
Effingham, Illinois, Spojené státy, 62401
- Saint Anthony Memorial Hospital
-
Eureka, Illinois, Spojené státy, 61530
- Illinois CancerCare-Eureka
-
Eureka, Illinois, Spojené státy, 61530
- Eureka Hospital
-
Galesburg, Illinois, Spojené státy, 61401
- Illinois CancerCare-Galesburg
-
Galesburg, Illinois, Spojené státy, 61401
- Galesburg Cottage Hospital
-
Havana, Illinois, Spojené státy, 62644
- Mason District Hospital
-
Havana, Illinois, Spojené státy, 62644
- Illinois CancerCare-Havana
-
Hopedale, Illinois, Spojené státy, 61747
- Hopedale Medical Complex - Hospital
-
Joliet, Illinois, Spojené státy, 60435
- Joliet Oncology-Hematology Associates Limited
-
Kewanee, Illinois, Spojené státy, 61443
- Illinois CancerCare-Kewanee Clinic
-
Kewanee, Illinois, Spojené státy, 61443
- Kewanee Hospital
-
Macomb, Illinois, Spojené státy, 61455
- Illinois CancerCare-Macomb
-
Macomb, Illinois, Spojené státy, 61455
- Mcdonough District Hospital
-
Monmouth, Illinois, Spojené státy, 61462
- Illinois CancerCare-Monmouth
-
Monmouth, Illinois, Spojené státy, 61462
- Holy Family Medical Center
-
Normal, Illinois, Spojené státy, 61761
- Community Cancer Center Foundation
-
Normal, Illinois, Spojené státy, 61761
- Bromenn Regional Medical Center
-
Normal, Illinois, Spojené státy, 61761
- Illinois CancerCare-Community Cancer Center
-
Ottawa, Illinois, Spojené státy, 61350
- Illinois CancerCare-Ottawa Clinic
-
Ottawa, Illinois, Spojené státy, 61350
- Ottawa Regional Hospital and Healthcare Center
-
Pekin, Illinois, Spojené státy, 61554
- Illinois CancerCare-Pekin
-
Pekin, Illinois, Spojené státy, 61554
- OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
-
Pekin, Illinois, Spojené státy, 61554
- Pekin Hospital
-
Peoria, Illinois, Spojené státy, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Spojené státy, 61615
- Illinois CancerCare-Peoria
-
Peoria, Illinois, Spojené státy, 61614
- Proctor Hospital
-
Peoria, Illinois, Spojené státy, 61603
- Methodist Medical Center of Illinois
-
Peru, Illinois, Spojené státy, 61354
- Illinois CancerCare-Peru
-
Peru, Illinois, Spojené státy, 61354
- Illinois Valley Hospital
-
Princeton, Illinois, Spojené státy, 61356
- Illinois CancerCare-Princeton
-
Princeton, Illinois, Spojené státy, 61356
- Perry Memorial Hospital
-
Spring Valley, Illinois, Spojené státy, 61362
- Saint Margaret's Hospital
-
Spring Valley, Illinois, Spojené státy, 61362
- Illinois CancerCare-Spring Valley
-
Urbana, Illinois, Spojené státy, 61801
- Carle Cancer Center
-
Urbana, Illinois, Spojené státy, 61801
- The Carle Foundation Hospital
-
-
Indiana
-
Michigan City, Indiana, Spojené státy, 46360
- Franciscan Saint Anthony Health-Michigan City
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic PC-William R Bliss Cancer Center
-
Cedar Rapids, Iowa, Spojené státy, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, Spojené státy, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, Spojené státy, 50325
- Medical Oncology and Hematology Associates-West Des Moines
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Spojené státy, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Spojené státy, 50309
- Medical Oncology and Hematology Associates-Des Moines
-
Des Moines, Iowa, Spojené státy, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa-Wide Oncology Research Coalition NCORP
-
Des Moines, Iowa, Spojené státy, 50314
- Medical Oncology and Hematology Associates-Laurel
-
Des Moines, Iowa, Spojené státy, 50307
- Mercy Capitol
-
Mason City, Iowa, Spojené státy, 50401
- Mercy Medical Center - North Iowa
-
Sioux City, Iowa, Spojené státy, 51101
- Siouxland Regional Cancer Center
-
Sioux City, Iowa, Spojené státy, 51104
- Saint Luke's Regional Medical Center
-
Sioux City, Iowa, Spojené státy, 51104
- Mercy Medical Center-Sioux City
-
-
Kansas
-
Anthony, Kansas, Spojené státy, 67003
- Hospital District Sixth of Harper County
-
Chanute, Kansas, Spojené státy, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Spojené státy, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Spojené státy, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Spojené státy, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Spojené státy, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Spojené státy, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Spojené státy, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Spojené státy, 67905
- Cancer Center of Kansas-Liberal
-
Liberal, Kansas, Spojené státy, 67901
- Southwest Medical Center
-
McPherson, Kansas, Spojené státy, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Spojené státy, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Spojené státy, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Spojené státy, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Spojené státy, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Spojené státy, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, Spojené státy, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Spojené státy, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Spojené státy, 67208
- Associates In Womens Health
-
Wichita, Kansas, Spojené státy, 67214
- Wichita NCI Community Oncology Research Program
-
Wichita, Kansas, Spojené státy, 67214
- Via Christi Regional Medical Center
-
Winfield, Kansas, Spojené státy, 67156
- Cancer Center of Kansas - Winfield
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106
- Saint Joseph Mercy Hospital
-
Ann Arbor, Michigan, Spojené státy, 48106
- Michigan Cancer Research Consortium NCORP
-
Battle Creek, Michigan, Spojené státy, 49017
- Bronson Battle Creek
-
Big Rapids, Michigan, Spojené státy, 49307
- Spectrum Health Big Rapids Hospital
-
Dearborn, Michigan, Spojené státy, 48124
- Beaumont Hospital-Dearborn
-
Detroit, Michigan, Spojené státy, 48236
- Saint John Hospital and Medical Center
-
Escanaba, Michigan, Spojené státy, 49829
- Green Bay Oncology - Escanaba
-
Flint, Michigan, Spojené státy, 48532
- Genesys Regional Medical Center-West Flint Campus
-
Flint, Michigan, Spojené státy, 48503
- Hurley Medical Center
-
Flint, Michigan, Spojené státy, 48503
- Genesys Hurley Cancer Institute
-
Grand Rapids, Michigan, Spojené státy, 49503
- Spectrum Health at Butterworth Campus
-
Grand Rapids, Michigan, Spojené státy, 49503
- Mercy Health Saint Mary's
-
Grand Rapids, Michigan, Spojené státy, 49503
- Cancer Research Consortium of West Michigan NCORP
-
Iron Mountain, Michigan, Spojené státy, 49801
- Green Bay Oncology - Iron Mountain
-
Jackson, Michigan, Spojené státy, 49201
- Allegiance Health
-
Lansing, Michigan, Spojené státy, 48912
- Sparrow Hospital
-
Livonia, Michigan, Spojené státy, 48154
- Saint Mary Mercy Hospital
-
Muskegon, Michigan, Spojené státy, 49444
- Mercy Health Mercy Campus
-
Pontiac, Michigan, Spojené státy, 48341
- Saint Joseph Mercy Oakland
-
Port Huron, Michigan, Spojené státy, 48060
- Lake Huron Medical Center
-
Saginaw, Michigan, Spojené státy, 48601
- Saint Mary's of Michigan
-
Traverse City, Michigan, Spojené státy, 49684
- Munson Medical Center
-
Warren, Michigan, Spojené státy, 48093
- Saint John Macomb-Oakland Hospital
-
Wyoming, Michigan, Spojené státy, 49519
- Metro Health Hospital
-
-
Minnesota
-
Alexandria, Minnesota, Spojené státy, 56308
- Medini, Eitan MD (UIA Investigator)
-
Bemidji, Minnesota, Spojené státy, 56601
- Sanford Clinic North-Bemidgi
-
Burnsville, Minnesota, Spojené státy, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, Spojené státy, 55433
- Mercy Hospital
-
Duluth, Minnesota, Spojené státy, 55805
- Essentia Health Cancer Center
-
Duluth, Minnesota, Spojené státy, 55805
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Spojené státy, 55805
- Miller-Dwan Hospital
-
Edina, Minnesota, Spojené státy, 55435
- Fairview-Southdale Hospital
-
Fergus Falls, Minnesota, Spojené státy, 56537
- Lake Region Healthcare Corporation-Cancer Care
-
Fergus Falls, Minnesota, Spojené státy, 56537
- Etzell, Paul S MD (UIA Investigator)
-
Fergus Falls, Minnesota, Spojené státy, 56537
- Swenson, Wade II, MD (UIA Investigator)
-
Fridley, Minnesota, Spojené státy, 55432
- Unity Hospital
-
Hutchinson, Minnesota, Spojené státy, 55350
- Hutchinson Area Health Care
-
Litchfield, Minnesota, Spojené státy, 55355
- Meeker County Memorial Hospital
-
Maplewood, Minnesota, Spojené státy, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, Spojené státy, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, Spojené státy, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, Spojené státy, 55407
- Abbott-Northwestern Hospital
-
Minneapolis, Minnesota, Spojené státy, 55407
- Virginia Piper Cancer Institute
-
Minneapolis, Minnesota, Spojené státy, 55407
- Minnesota Cooperative Group Outreach Program
-
New Ulm, Minnesota, Spojené státy, 56073
- New Ulm Medical Center
-
Robbinsdale, Minnesota, Spojené státy, 55422
- North Memorial Medical Health Center
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo Clinic
-
Saint Cloud, Minnesota, Spojené státy, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Cloud, Minnesota, Spojené státy, 56303
- Saint Cloud Hospital
-
Saint Louis Park, Minnesota, Spojené státy, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Louis Park, Minnesota, Spojené státy, 55416
- Metro Minnesota Community Oncology Research Consortium
-
Saint Paul, Minnesota, Spojené státy, 55101
- Regions Hospital
-
Saint Paul, Minnesota, Spojené státy, 55102
- United Hospital
-
Saint Paul, Minnesota, Spojené státy, 55102
- Saint Joseph's Hospital - Healtheast
-
Shakopee, Minnesota, Spojené státy, 55379
- Saint Francis Regional Medical Center
-
Stillwater, Minnesota, Spojené státy, 55082
- Lakeview Hospital
-
Waconia, Minnesota, Spojené státy, 55387
- Ridgeview Medical Center
-
Willmar, Minnesota, Spojené státy, 56201
- Rice Memorial Hospital
-
Woodbury, Minnesota, Spojené státy, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
Woodbury, Minnesota, Spojené státy, 55125
- Woodwinds Health Campus
-
-
Nebraska
-
Lincoln, Nebraska, Spojené státy, 68510
- Nebraska Cancer Research Center
-
Omaha, Nebraska, Spojené státy, 68124
- Alegent Health Bergan Mercy Medical Center
-
Omaha, Nebraska, Spojené státy, 68122
- Alegent Health Immanuel Medical Center
-
Omaha, Nebraska, Spojené státy, 68130
- Alegent Health Lakeside Hospital
-
Omaha, Nebraska, Spojené státy, 68131
- Creighton University Medical Center
-
Omaha, Nebraska, Spojené státy, 68106
- Missouri Valley Cancer Consortium
-
-
North Carolina
-
Rutherfordton, North Carolina, Spojené státy, 28139
- Rutherford Hospital
-
Winston-Salem, North Carolina, Spojené státy, 27104
- Southeast Clinical Oncology Research (SCOR) Consortium NCORP
-
-
North Dakota
-
Bismarck, North Dakota, Spojené státy, 58501
- Sanford Bismarck Medical Center
-
Bismarck, North Dakota, Spojené státy, 58501
- Mid Dakota Clinic
-
Bismarck, North Dakota, Spojené státy, 58501
- Saint Alexius Medical Center
-
Fargo, North Dakota, Spojené státy, 58122
- Sanford Broadway Medical Center
-
Fargo, North Dakota, Spojené státy, 58122
- Sanford Clinic North-Fargo
-
Fargo, North Dakota, Spojené státy, 58122
- Roger Maris Cancer Center
-
Grand Forks, North Dakota, Spojené státy, 58201
- Altru Cancer Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, Spojené státy, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Bethlehem, Pennsylvania, Spojené státy, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Danville, Pennsylvania, Spojené státy, 17822
- Geisinger Medical Center
-
Hazleton, Pennsylvania, Spojené státy, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
State College, Pennsylvania, Spojené státy, 16801
- Geisinger Medical Group
-
Wilkes-Barre, Pennsylvania, Spojené státy, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Anderson, South Carolina, Spojené státy, 29621
- AnMed Health Cancer Center
-
Anderson, South Carolina, Spojené státy, 29621
- AnMed Health Hospital
-
Greenville, South Carolina, Spojené státy, 29601
- Saint Francis Hospital
-
Spartanburg, South Carolina, Spojené státy, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Rapid City, South Dakota, Spojené státy, 57701
- Rapid City Regional Hospital
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Spojené státy, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Spojené státy, 57104
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Medical X-Ray Center
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Avera McKennan Hospital and University Health Center
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Cancer Center
-
Richmond, Virginia, Spojené státy, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Washington
-
Seattle, Washington, Spojené státy, 98101
- Virginia Mason Medical Center
-
-
Wisconsin
-
Green Bay, Wisconsin, Spojené státy, 54301
- Saint Vincent Hospital Cancer Center Green Bay
-
Green Bay, Wisconsin, Spojené státy, 54303
- Saint Vincent Hospital Cancer Center at Saint Mary's
-
Green Bay, Wisconsin, Spojené státy, 54303
- Green Bay Oncology Limited at Saint Mary's Hospital
-
Green Bay, Wisconsin, Spojené státy, 54301-3526
- Green Bay Oncology at Saint Vincent Hospital
-
Manitowoc, Wisconsin, Spojené státy, 54221
- Holy Family Memorial Hospital
-
Marinette, Wisconsin, Spojené státy, 54143
- Bay Area Medical Center
-
Oconto Falls, Wisconsin, Spojené státy, 54154
- Green Bay Oncology - Oconto Falls
-
Sheboygan, Wisconsin, Spojené státy, 53081
- HSHS Saint Nicholas Hospital
-
Sturgeon Bay, Wisconsin, Spojené státy, 54235
- Green Bay Oncology - Sturgeon Bay
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Central pathology review submission; this review is mandatory prior to registration to confirm eligibility; it should be initiated as soon after surgery as possible
- =< 2 prior systemic chemotherapy regimens
- Histological confirmation of a grade 4 astrocytoma (glioblastoma) or gliosarcoma, at primary diagnosis or recurrence by World Health Organization (WHO) criteria; central pathology review is mandatory prior to study entry to confirm eligibility
- Evidence of tumor progression by magnetic resonance imaging (MRI) or computed tomography (CT) scan following radiation therapy (RT) or following the most recent anti-tumor therapy
- Bidimensionally measurable or evaluable disease by MRI or CT scan
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
- >= 12 weeks since the completion of RT
- Fixed or decreasing dose of corticosteroids (or no corticosteroids) >= 1 week prior to registration
- >= 1 week from minor surgery other than venous line placement and > 3 weeks from major surgery (except for patients undergoing tumor tissue acquisition)
- >= 4 weeks since prior cytotoxic chemotherapy (>= 6 weeks for nitrosoureas)
- >= 2 weeks from cytostatic chemotherapy such as tamoxifen, cis-retinoic acid, or thalidomide (address questions regarding such agents to study chair)
- White blood cells (WBC) >= 3,000/mm^3
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Hemoglobin (Hgb) >= 10 gm/dL
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x ULN
- Creatinine =< 2.0 x ULN
- Serum cholesterol =< 350 mg/dL
- Serum triglycerides =< 400 mg/dL
- Willingness to provide the biologic specimens as required by the protocol; (please note that the willingness to participate pertains only to the patient and does not factor in the institution?s ability to participate in any part of the translational component)
Exclusion Criteria:
- Prior intratumoral chemotherapy (e.g., Gliadel or IL13-PE38QQR), stereotactic radiosurgery, or interstitial brachytherapy unless there is a separate lesion on MRI which is not part of the previous treatment field or there is proof of recurrent disease based on biopsy, MRI spectroscopy, or positron emission tomography (PET) scan
- Prior CCI-779, sorafenib, or other agents specifically targeting mammalian target of rapamycin (mTOR) or raf; patients receiving prior agents inhibiting VEGF or VEGF receptor (R) (prior anti-VEGF group) are eligible but: 1) must be at least four weeks from last treatment with the agent(s); and 2) must have recovered from any clinically relevant toxicities attributable to this agent(s)
Evidence of bleeding diathesis or coagulopathy
- Note: Patients on prophylactic anticoagulation therapy (e.g., low-dose warfarin) are eligible provided their coagulation parameter levels are as follows: prothrombin time (International Normalized Ratio [INR] of prothrombin time) < 1.1 x institutional upper limit of normal
- Note: Patients on full-dose anticoagulants (e.g., warfarin) are eligible provided that both of the following criteria are met: a) the patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin, and b) the patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- International normalized ration (INR) > 1.5 (unless the patient is on full-dose warfarin)
- Receiving enzyme-inducing antiepileptic drugs (EIAEDs; e.g., phenytoin, fosphenytoin, carbamazepine, phenobarbital, or primidone) or any other potent cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inducer, such as rifampin or St. John?s wort
- Any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow pills
- Hypertension with systolic blood pressure of > 140 mmHg or diastolic pressure > 90 mmHg; however, patients with well-controlled hypertension are eligible
- Uncontrolled infection
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate contraception
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Known hypersensitivity to any of the components of CCI-779 or sorafenib
- Other active malignancy
- Uncontrolled intercurrent illness, including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness/social situation that would preclude study compliance with study requirements
- Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive; HIV-positive patients on combination antiretroviral therapy are ineligible
- Receiving any investigational agents other than CCI-779 and sorafenib
- Significant intratumoral, intracerebral, or subarachnoid hemorrhage on baseline MRI or CT, or other history of significant intratumoral, intracerebral, or subarachnoid hemorrhage
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Group I (sorafenib tosylate, temsirolimus)
Patients receive sorafenib tosylate and temsirolimus as in Phase I.
|
Korelační studie
Vzhledem k tomu, IV
Ostatní jména:
Vzhledem k PO
Ostatní jména:
|
Experimentální: Group II (sorafenib tosylate, temsirolimus, surgery)
Patients receive sorafenib tosylate PO BID on days 1-8 and temsirolimus IV over 30 minutes on day 1.
Patients undergo surgery on day 8.
After recovering from surgery, patients receive sorafenib tosylate and temsirolimus as in Phase I.
|
Korelační studie
Podstoupit operaci
Vzhledem k tomu, IV
Ostatní jména:
Vzhledem k PO
Ostatní jména:
|
Experimentální: Group III (sorafenib tosylate, temsirolimus, anti-VEGF)
Patients who have received prior anti-VEGF therapy and are not undergoing surgery receive sorafenib tosylate and temsirolimus as in Phase I.
|
Korelační studie
Vzhledem k tomu, IV
Ostatní jména:
Vzhledem k PO
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Progression-free Survival
Časové okno: At 6 months
|
The primary endpoint is the proportion of patients alive and progression-free 6 months after study treatment initiation. If more than 41 evaluable patients are accrued in group 1 or group 3, the additional patients will not be used to evaluate the decision rule for that group or otherwise used in any decision-making processes. However, they will be included in the final point and confidence interval estimates for that group. The 'success' probability, i.e., 6-month progression-free survival percentage, for each of group 1 and group 3 will be estimated as the number of evaluable patients still alive at 6 months divided by the total number of evaluable patients followed for at least 6 months. Ninety-five percent confidence intervals for the 'success' probability will be calculated according to the approach of Duffy and Santner. Progression is defined as a 25% increase in product of perpendicular diameters of contrast enhancement or mass or appearance of new lesions. |
At 6 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Overall Survival
Časové okno: From start of study registration to death due to any cause or until last follow-up, up to 5 years
|
The overall survival distribution will be estimated using the method of Kaplan-Meier.
|
From start of study registration to death due to any cause or until last follow-up, up to 5 years
|
Objective Response, as Determined by a Neurological Exam, MRI, and/or CT Measurement
Časové okno: Up to 5 years
|
The proportion of patients in each response category will be summarized and 90% confidence intervals calculated assuming that the incidence of response is binomially distributed.
|
Up to 5 years
|
Progression-free Survival
Časové okno: Time from study registration to date of disease progression or last follow-up, assessed up to 5 years
|
Kaplan-Meier survival curves will be used to estimate progression-time distributions.
|
Time from study registration to date of disease progression or last follow-up, assessed up to 5 years
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Kurt Jaeckle, Alliance for Clinical Trials in Oncology
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Patologické procesy
- Onemocnění mozku
- Onemocnění centrálního nervového systému
- Nemoci nervového systému
- Novotvary podle histologického typu
- Novotvary
- Novotvary podle místa
- Novotvary, žlázové a epiteliální
- Atributy nemoci
- Astrocytom
- Gliom
- Novotvary, neuroepiteliální
- Neuroektodermální nádory
- Novotvary, zárodečné buňky a embryonální
- Novotvary, nervová tkáň
- Novotvary centrálního nervového systému
- Novotvary nervového systému
- Glioblastom
- Opakování
- Novotvary mozku
- Gliosarkom
- Fyziologické účinky léků
- Molekulární mechanismy farmakologického působení
- Antiinfekční látky
- Inhibitory enzymů
- Antineoplastická činidla
- Imunosupresivní látky
- Imunologické faktory
- Antibakteriální látky
- Inhibitory proteinkinázy
- Antibiotika, antineoplastika
- Antifungální látky
- Sorafenib
- Sirolimus
Další identifikační čísla studie
- NCI-2009-00652 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- U10CA180821 (Grant/smlouva NIH USA)
- U10CA025224 (Grant/smlouva NIH USA)
- CDR0000472240
- NCCTG-N0572
- N0572 (Jiný identifikátor: CTEP)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Glioblastom dospělých
-
Coeptis TherapeuticsDuke UniversityNáborMDS | AML, Adult RecurrentSpojené státy
-
Shengke Pharmaceuticals (Jiangsu) Limited, ChinaNáborAML, Adult Recurrent | NHL, dospělíČína
-
MacroGenicsJiž není k dispoziciAkutní myeloidní leukémie | AML | AML, Adult Recurrent
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... a další spolupracovníciNáborGlioblastom | Multiformní glioblastom | Glioblastom, IDH divokého typu | Multiformní glioblastom, dospělý | Multiformní glioblastom mozkuSpojené státy, Belgie, Švýcarsko, Německo, Holandsko
-
Celldex TherapeuticsDokončenoGlioblastom | Gliosarkom | Recidivující glioblastom | Malobuněčný glioblastom | Giant Cell Glioblastom | Glioblastom S Oligodendrogliální Složkou | Recidivující glioblastomSpojené státy
-
Jasper GerritsenMassachusetts General Hospital; Universitaire Ziekenhuizen KU Leuven; University... a další spolupracovníciNáborGlioblastom | Multiformní glioblastom | Recidivující glioblastom | Glioblastom, IDH divokého typu | Multiformní glioblastom, dospělý | Multiformní glioblastom mozku | Astrocytom mozku | Astrocytom, maligníSpojené státy, Německo, Holandsko, Švýcarsko, Belgie
-
University Hospital, GenevaAktivní, ne náborMultiformní glioblastom | Multiformní glioblastom mozku | Gliom mozku | Glioblastom, dospělýŠvýcarsko
-
PureTechNábor
-
Milton S. Hershey Medical CenterNáborGlioblastom | Multiformní glioblastom | Multiformní glioblastom, dospělý | Multiformní glioblastom mozkuSpojené státy
-
Leland MethenyNational Cancer Institute (NCI)NáborMultiformní glioblastom | Supratentoriální gliosarkom | Multiformní glioblastom, dospělý | Supratentoriální glioblastomSpojené státy
Klinické studie na Laboratorní analýza biomarkerů
-
Istituto per la Ricerca e l'Innovazione BiomedicaNábor
-
University of VirginiaNeznámý
-
IRCCS Eugenio MedeaNáborPoruchou autistického spektra | Včasná intervenceItálie
-
Chang Gung Memorial HospitalNeznámýNosní onemocněníTchaj-wan
-
Rio de Janeiro State UniversityCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional... a další spolupracovníciDokončenoKardiovaskulární choroby | Nedostatek vitaminu D | Stavy související s menopauzouBrazílie
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Zatím nenabírámeRakovina děložního tělíska ve stádiu I | Rakovina děložního tělíska II | Rakovina děložního tělíska ve stádiu III | Rakovina děložního těla ve stádiu IV | Endometriální serózní adenokarcinomSpojené státy